What is Pasithea Therapeutics's market cap?

Pasithea Therapeutics (KTTA) has a market capitalization of $15.0M and trades on NASDAQ.

Who are Pasithea Therapeutics's competitors?

Pasithea Therapeutics's key competitors include Merck & Co., Inc., Pfizer Inc., Verastem, Inc., and others. These companies compete in similar markets and product categories.

Who does Pasithea Therapeutics partner with?

Pasithea Therapeutics's notable partners include WuXi AppTec, Evotec, FightMND, and others.

What subsidiaries does Pasithea Therapeutics have?

Pasithea Therapeutics's subsidiaries include AlloMek Therapeutics, LLC, Alpha-5 Integrin, LLC.

Where is Pasithea Therapeutics headquartered?

Pasithea Therapeutics is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2021.

Pasithea Therapeutics

KTTA

Pasithea Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for RASopathies, MAPK pathway-driven tumors, and central nervous system disorders.

Market cap

$15.04M+176%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

EPS-$0.12Beat by $0.33

Read the full report

Next report

Date not yet announced

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

CytomX Therapeutics$707.5M+87.9%

Verastem$534.3M+61.5%

Foghorn Therapeutics$305.3M-15.7%

ProMIS Neurosciences$105.1M+257%

Gain Therapeutics$79.3M+41.7%

Pasithea Therapeutics$15.0M+171%

By revenue growth

Merck & Co.+2.9%

Pfizer+1.4%

CytomX Therapeutics-75.9%

By net margin

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

CytomX Therapeutics-166.4%-195pp

Profile

Pasithea Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for RASopathies, MAPK pathway-driven tumors, and central nervous system disorders. The company's primary focus is on advancing its lead macrocyclic MEK inhibitor, PAS-004, which is designed to offer superior safety, tolerability, and pharmacokinetic profiles compared to existing therapies. By targeting unmet medical needs in conditions like Neurofibromatosis type 1 (NF1) and schizophrenia, the company aims to establish a leading position in precision medicine for genetic and inflammatory diseases.

Competitive position

A clinical-stage developer of next-generation macrocyclic MEK inhibitors seeking to overcome the toxicity and dosing limitations of first-generation standard-of-care treatments.

GeographiesUnited States, Australia, South Korea, Eastern Europe

Customer segmentsRare Disease Patients, Oncology Patients, Psychiatric Patients

Business modelResearch and Development, Drug Discovery

SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Academic Research Institutions, Raw Material Suppliers

CustomersSpecialty Pharmacies, Hospitals, Healthcare Providers, Pharmaceutical Distributors

CountryUnited States of America

Listed2021

Employees8.0

CEOTiago Reis Marques

SectorHealthcare

IndustryBiotechnology

Websitepasithea.com

FilingsSEC EDGAR

Questions, answered.

What is Pasithea Therapeutics's market cap?: Pasithea Therapeutics (KTTA) has a market capitalization of $15.0M and trades on NASDAQ.
Who are Pasithea Therapeutics's competitors?: Pasithea Therapeutics's key competitors include Merck & Co., Inc., Pfizer Inc., Verastem, Inc., and others. These companies compete in similar markets and product categories.
Who does Pasithea Therapeutics partner with?: Pasithea Therapeutics's notable partners include WuXi AppTec, Evotec, FightMND, and others.
What subsidiaries does Pasithea Therapeutics have?: Pasithea Therapeutics's subsidiaries include AlloMek Therapeutics, LLC, Alpha-5 Integrin, LLC.
Where is Pasithea Therapeutics headquartered?: Pasithea Therapeutics is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2021.